PADCEV (enfortumab-vedotin) is an agent for the treatment of metastatic urothelial cancer. The product was initially launched in 2019 and received full approval for front-line treatment of la/mUC in December 2023. PADCEV, in combination with pembrolizumab, has demonstrated significant efficacy relative to platinum-based therapy and is now recognized as the next standard of care in front-line la/mUC. PADCEV is a “high priority” brand within the Pfizer Oncology portfolio and is a key growth driver for the organization. The brand recently launched it’s initial MIBC indication in the cis-ineligible population and is currently preparing for the second launch in the cis-eligible population. This role is focused on the la/mUC indication and evolving the narrative to produce continued growth while balancing the needs of the MIBC launch. This indication is critical to the brand and will be the main revenue driver the remainder of the brand lifecycle. Therefore, appropriate attention and promotion will be vital to brand performance. In addition, this role will be responsible for developing Urology strategies to support MIBC launches. It is critical for a candidate to have a deep understanding of the Community Urologists vs Academics and how they interact and refer to Medical Oncologists. This will be a major factor to the uptake in utilization for the MIBC indication(s). Due to the alliance and colleagues around the country, candidates must be flexible with working hours to accommodate ET, CT, and PT time zones. Strong communication, actively contributing to a positive team culture, working through ambiguity, quick learning agility, working on a high matrix team, and ability to perform in incredibly fast paced environments are critical for success on PADCEV.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Number of Employees
5,001-10,000 employees